Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
Alpha Cognition (Nasdaq: ACOG) has officially launched ZUNVEYL (Benzgalantamine), the first FDA-approved oral treatment for mild to moderate Alzheimer's disease in the past decade. The company has deployed a 32-person sales team targeting the $2 billion Long-Term-Care market.
The commercial team, averaging 16 years of industry sales experience and 10 years in long-term care, is now actively engaging with healthcare providers nationwide. ZUNVEYL is available in three doses (5 mg, 10 mg, and 15 mg) through pharmacies across the country.
Lauren D'Angelo, Chief Operating Officer and Chief Commercial Officer, emphasized that all launch activities were delivered on-time and on-budget, positioning ZUNVEYL for success in providing a differentiated treatment option for Alzheimer's patients.
Alpha Cognition (Nasdaq: ACOG) ha ufficialmente lanciato ZUNVEYL (Benzgalantamina), il primo trattamento orale approvato dalla FDA per l'Alzheimer da lieve a moderato negli ultimi dieci anni. L'azienda ha attivato un team di vendita composto da 32 persone che si rivolge al mercato della cura a lungo termine da 2 miliardi di dollari.
Il team commerciale, con una media di 16 anni di esperienza nelle vendite nel settore e 10 anni nella cura a lungo termine, sta ora interagendo attivamente con i fornitori di assistenza sanitaria in tutto il paese. ZUNVEYL è disponibile in tre dosaggi (5 mg, 10 mg e 15 mg) presso le farmacie di tutto il territorio nazionale.
Lauren D'Angelo, Chief Operating Officer e Chief Commercial Officer, ha sottolineato che tutte le attività di lancio sono state completate nei tempi e nel budget previsti, posizionando ZUNVEYL per avere successo nel fornire un'opzione terapeutica differenziata per i pazienti affetti da Alzheimer.
Alpha Cognition (Nasdaq: ACOG) ha lanzado oficialmente ZUNVEYL (Benzgalantamina), el primer tratamiento oral aprobado por la FDA para la enfermedad de Alzheimer leve a moderada en la última década. La empresa ha desplegado un equipo de ventas de 32 personas que se dirige al mercado de cuidado a largo plazo de 2 mil millones de dólares.
El equipo comercial, con un promedio de 16 años de experiencia en ventas en la industria y 10 años en cuidado a largo plazo, ahora está interactuando activamente con proveedores de atención médica en todo el país. ZUNVEYL está disponible en tres dosis (5 mg, 10 mg y 15 mg) a través de farmacias en todo el país.
Lauren D'Angelo, Directora de Operaciones y Directora Comercial, enfatizó que todas las actividades de lanzamiento se entregaron a tiempo y dentro del presupuesto, posicionando a ZUNVEYL para el éxito al proporcionar una opción de tratamiento diferenciada para los pacientes con Alzheimer.
알파 코그니션 (Nasdaq: ACOG)은 지난 10년간 경증에서 중등도 알츠하이머병에 대해 FDA 승인을 받은 최초의 경구 치료제인 ZUNVEYL (벤즈갈란타민)을 공식 출시했습니다. 이 회사는 20억 달러 규모의 장기 요양 시장을 목표로 하는 32명으로 구성된 판매팀을 배치했습니다.
상업 팀은 평균 16년의 산업 판매 경험과 10년의 장기 요양 경험을 가지고 있으며, 현재 전국의 의료 제공자와 적극적으로 소통하고 있습니다. ZUNVEYL은 전국의 약국에서 3가지 용량(5mg, 10mg, 15mg)으로 제공됩니다.
로렌 댄젤로 COO 겸 상업 책임자는 모든 출시 활동이 제시간에 예산 내에서 완료되었다고 강조하며, ZUNVEYL이 알츠하이머 환자에게 차별화된 치료 옵션을 제공하는 데 성공할 수 있도록 자리매김하고 있다고 밝혔습니다.
Alpha Cognition (Nasdaq: ACOG) a officiellement lancé ZUNVEYL (Benzgalantamine), le premier traitement oral approuvé par la FDA pour la maladie d'Alzheimer légère à modérée au cours de la dernière décennie. L'entreprise a déployé une équipe de vente de 32 personnes ciblant le marché des soins de longue durée de 2 milliards de dollars.
L'équipe commerciale, avec une moyenne de 16 ans d'expérience dans les ventes et 10 ans dans les soins de longue durée, engage désormais activement des discussions avec des prestataires de soins de santé à l'échelle nationale. ZUNVEYL est disponible en trois dosages (5 mg, 10 mg et 15 mg) dans les pharmacies à travers le pays.
Lauren D'Angelo, Directrice des opérations et Directrice commerciale, a souligné que toutes les activités de lancement ont été réalisées à temps et dans le budget, positionnant ZUNVEYL pour réussir à fournir une option de traitement différenciée pour les patients atteints d'Alzheimer.
Alpha Cognition (Nasdaq: ACOG) hat offiziell ZUNVEYL (Benzgalantamin) eingeführt, die erste von der FDA genehmigte orale Behandlung für leichte bis mittelschwere Alzheimer-Krankheit in den letzten zehn Jahren. Das Unternehmen hat ein 32-köpfiges Verkaufsteam eingesetzt, das den 2-Milliarden-Dollar-Markt für Langzeitpflege anvisiert.
Das Verkaufsteam, das im Durchschnitt 16 Jahre Erfahrung im Vertrieb und 10 Jahre in der Langzeitpflege hat, ist nun aktiv im Austausch mit Gesundheitsdienstleistern im ganzen Land. ZUNVEYL ist in drei Dosierungen (5 mg, 10 mg und 15 mg) in Apotheken im ganzen Land erhältlich.
Lauren D'Angelo, Chief Operating Officer und Chief Commercial Officer, betonte, dass alle Launch-Aktivitäten pünktlich und im Budgetrahmen durchgeführt wurden, wodurch ZUNVEYL für den Erfolg positioniert wird, eine differenzierte Behandlungsoption für Alzheimer-Patienten bereitzustellen.
- First FDA-approved oral Alzheimer's treatment in 10 years
- Targeting $2B Long-Term-Care market opportunity
- Experienced sales team with average 16 years industry experience
- Launch activities completed on-time and on-budget
- Nationwide pharmacy distribution network established
- None.
Insights
Alpha Cognition's commercial launch of ZUNVEYL marks a transformative milestone that shifts the company from development-stage to commercial revenue generation. For a company with just
The execution precision demonstrated by completing all launch activities on-time and on-budget showcases operational discipline - a critical quality many small biotechs lack during their first commercial transition. The 32-person sales force with extensive experience (averaging 16 years in industry and 10 years in long-term care specifically) represents appropriate investment in commercialization infrastructure targeting the highest-value segment of the Alzheimer's market.
ZUNVEYL's position as the first oral FDA-approved Alzheimer's treatment in a decade provides a meaningful differentiation point for physicians and patients. The simultaneous launch of three dosage strengths (5mg, 10mg, 15mg) enables personalized treatment approaches that could enhance adoption rates. The nationwide availability through standard pharmacy channels eliminates distribution bottlenecks that often hamper biotech product launches.
While investors should monitor initial payer coverage decisions and early adoption metrics in coming quarters, this launch represents a well-executed commercialization of a product addressing significant unmet needs in a substantial market. The comprehensive commercial preparation suggests management's strategic focus on maximizing ZUNVEYL's market penetration potential.
ZUNVEYL (Benzgalantamine) enters the Alzheimer's treatment landscape as the first new oral FDA-approved option in ten years, addressing a significant therapeutic gap for the millions affected by mild to moderate disease. This approval represents meaningful progress in a therapeutic area that has seen innovation in symptomatic treatments despite substantial research investment.
The strategic focus on the
Clinically, the availability of three distinct dosage strengths (5mg, 10mg, 15mg) enables critical dose optimization - particularly important in elderly patients who frequently exhibit variable drug responses and tolerance. This flexibility allows physicians to balance efficacy with side effect management, potentially improving adherence and treatment persistence.
The nationwide pharmacy accessibility removes geographic barriers to treatment, which is particularly valuable for caregivers of Alzheimer's patients who often face significant logistical challenges managing care. While launch success will ultimately depend on real-world efficacy, safety profile, and payer coverage, ZUNVEYL represents a meaningful addition to the therapeutic arsenal available for this devastating neurodegenerative condition.
ZUNVEYL is the first oral FDA-approved treatment for Alzheimer’s disease in the past decade
32 person sales team hired to cover the
All launch activities delivered on-time and on-budget, positioning ZUNVEYL for success
With a highly experienced commercial team in place, including industry leaders with proven success in the long-term care market, Alpha Cognition is poised to make a powerful impact. The company’s nationwide salesforce is fully deployed and actively engaging with healthcare providers to ensure that ZUNVEYL reaches the patients who need it most. The commercial strategy is specifically designed to address the unique challenges of the long-term care market, the largest segment for Alzheimer’s disease, and a
"The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease," said Lauren D’Angelo, Chief Operating Officer and Chief Commercial Officer of Alpha Cognition. "Our team has worked relentlessly to bring this treatment to market — from building out an industry-leading infrastructure to hiring a top notch sales team — all in record time. I’m incredibly proud of the dedication and expertise of our team, and we are excited to partner with healthcare professionals to ensure that patients receive the care they deserve."
Alpha Cognition’s commercial team includes top talent with deep expertise in Alzheimer’s disease and long-term care. The sales team has, on average, 16 years of industry sales experience and 10 years of experience selling in the long-term care market. This veteran team is focused on driving rapid adoption of ZUNVEYL and ensuring that patients have access to ZUNVEYL from day one.
ZUNVEYL is designed to provide a differentiated treatment option for patients with mild to moderate Alzheimer’s disease, offering an alternative for those who may have limited options. With the commercial launch now underway, Alpha Cognition is engaging with healthcare providers, payers, and caregivers to support patient access and education. Patients can now access ZUNVEYL in three doses (5 mg, 10 mg, and 15 mg) through a prescription that can be filled at pharmacies nationwide.
To learn more about ZUNVEYL, visit ZUNVEYL.com.
About ZUNVEYL
ZUNVEYL (benzgalantamine) is a twice-daily treatment designed to address the cognitive symptoms of mild-to-moderate Alzheimer’s disease. By enhancing cholinergic function in the brain, ZUNVEYL supports memory, learning, and overall cognitive function, offering a meaningful improvement for patients and their caregivers.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
For more information, please visit www.alphacognition.com.
INDICATION AND USAGE
ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.
WARNINGS AND PRECAUTIONS
Serious Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered.
Anesthesia: See Drug Interactions Section
Cardiovascular Conditions: Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction.
Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.
Gastrointestinal Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.
Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL.
Genitourinary Conditions: Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction.
Neurological Conditions: Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL.
Pulmonary Conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions.
ADVERSE REACTIONS
The most common adverse reactions with galantamine tablets (≥
DRUG INTERACTIONS
Use with Anticholinergics: Galantamine has the potential to interfere with the activity of anticholinergic medications.
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data may cause fetal harm.
Hepatic Impairment: In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.
Renal Impairment: In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended.
These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the, the long-term benefits of ZUNVEYL, the Company’s timing and planned activities and business strategy to launch ZUNVEYL, the potential timing for the availability of ZUNVEYL, the potential future developments of ZUNVEYL, the market size and demand for ZUNVEYL and the Company’s potential growth opportunities, capital requirements,. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks related to our focus on the long-term care market, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with Canadian securities regulatory authorities and available at www.sedar.com and the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1/A registration statement as filed with the SEC on January 10, 2025 and available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319665873/en/
Investor Contact:
Alpha Cognition Inc.
Email: ir@alphacognition.com
Source: Alpha Cognition Inc.
FAQ
What is ZUNVEYL and how is it significant for Alzheimer's treatment?
How large is the market opportunity for ACOG's ZUNVEYL in the Long-Term-Care segment?
What is the experience level of ACOG's commercial team for ZUNVEYL?
How can patients access ZUNVEYL following its commercial launch?
